Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

Academisch Ziekenhuis Leiden

Other

Reinaldus Everardus Maria Toes

Leendert Adrianus Trouw

Thomas Willem Johannes Huizinga

Jing Shi

Anthony Cerami

Petrus Antonius Van Veelen

Cornelis Johannes Maria Melief

Rienk Offringa

Annemieke Geluk

Maria Johanna Philomena Schoenmaekers-Welters

Annemieke M De Jong

Sjoerd Hendrikus Van Der Burg

Tom H M Ottenhoff

Hans Ulrich Scherer

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

Fab-linked glycans as biomarker for the transition from a pre-disease 'at-risk-phase' to rheumatoid arthritis; AAV or Sjögren syndrome

Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.

Anti-carbamylated protein antibodies and the risk for arthritis

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides. Also disclosed are clinically relevant approaches for vaccination and/or treatment of subjects against HPV and methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer.

Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses

Growing community of inventors

Leiden, Netherlands

Reinaldus Everardus Maria Toes